Literature DB >> 35378513

miRNA-29 aggravates myocardial infarction via inhibiting the PI3K/mTOR/HIF1α/VEGF pathway.

Xiaoxi Wang1, Yanning Liu2, Huiqing Hou3, Weihua Shao4, Dai Huang5, Zhihua Hao3, Hongyuan Xue5, Yuquan Ye6.   

Abstract

INTRODUCTION: MI is defined by the presence of myocardial necrosis, which is caused by acute and persistent ischemia and hypoxia of the coronary artery. In recent years, its incidence rate has been on the rise in China.
METHODS: GSE34198, GSE97320 and GSE141512 datasets were download for DEG analysis. KEGG pathway analysis, GO analysis, GSEA and PPI network construction were performed. Later, target genes of candidate miRNAs were predicted. Next, echocardiography was conducted to detect the effects of miR-29 on left ventricular structure and cardiac function in vivo, and H&E staining was adopted to study the effects of miR-29 on angiogenesis and fibrosis in vivo. Furthermore, Western blotting was employed to investigate the effects of miR-29 inhibition on the expressions of proteins related to the PI3K\mTOR\ HIF-1α\VEGF pathway.
RESULTS: There were 162 DEGs involved in MI. GO analysis revealed that inflammatory responses, negative regulation of apoptosis and innate immune response were the main enriched biological processes. KEGG analysis manifested that DEGs were mainly enriched in the PI3K/Akt signaling pathway, and GSEA demonstrated that they were mainly enriched in the PI3K/Akt/mTOR, HIF and VEGF pathways. Moreover, target gene prediction showed that miR-29 was lowly expressed in MI. According to Masson's trichrome staining, miR-29 inhibition promoted angiogenesis, reduced fibrosis, and increased the protein expressions of p-PI3K, p-mTOR, HIF-1α, and VEGF.
CONCLUSIONS: MiR-29 may play an important role in the growth and development of MI. After inhibition of miR-29, the PI3K/mTOR/HIF-1α/VEGF pathway is activated to alleviate MI.

Entities:  

Keywords:  PI3K/mTOR/HIF1α/VEGF pathway; bioinformatics; miRNA-29; myocardial infarction

Mesh:

Substances:

Year:  2022        PMID: 35378513      PMCID: PMC9037277          DOI: 10.18632/aging.203997

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  28 in total

Review 1.  Clinicopathological complexity in the application of the universal definition of myocardial infarction.

Authors:  Louis Maximilian Buja; Bradley Zehr; Laura Lelenwa; Eze Ogechukwu; Bihong Zhao; Amitava Dasgupta; Rolf F Barth
Journal:  Cardiovasc Pathol       Date:  2019-10-10       Impact factor: 2.185

Review 2.  A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin.

Authors:  Corrie L Gallant-Behm; Joseph Piper; Joshua M Lynch; Anita G Seto; Seok Jong Hong; Thomas A Mustoe; Catherine Maari; Linda A Pestano; Christina M Dalby; Aimee L Jackson; Paul Rubin; William S Marshall
Journal:  J Invest Dermatol       Date:  2018-11-22       Impact factor: 8.551

3.  LncRNA HULC alleviates HUVEC inflammation and improves angiogenesis after myocardial infarction through down-regulating miR-29b.

Authors:  Z-L Chen; Y-X Chen; J Zhou; Y Li; C-Y Gong; X-B Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-06       Impact factor: 3.507

4.  Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction.

Authors:  S Robinson; M Follo; D Haenel; M Mauler; D Stallmann; M Tewari; D Duerschmied; K Peter; C Bode; I Ahrens; M Hortmann
Journal:  Int J Cardiol       Date:  2018-04-15       Impact factor: 4.164

5.  Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.

Authors:  Mathieu Kerneis; Johanne Silvain; Jérémie Abtan; Marie Hauguel; Olivier Barthélémy; Laurent Payot; Delphine Brugier; Sophie Galier; Jean-Philippe Collet; Gilles Montalescot
Journal:  Arch Cardiovasc Dis       Date:  2015-06-22       Impact factor: 2.340

6.  miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.

Authors:  Marco Rossi; Maria Rita Pitari; Nicola Amodio; Maria Teresa Di Martino; Francesco Conforti; Emanuela Leone; Cirino Botta; Francesco Maria Paolino; Teresa Del Giudice; Eleonora Iuliano; Michele Caraglia; Manlio Ferrarini; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

7.  MicroRNA 29b functions in acute myeloid leukemia.

Authors:  Ramiro Garzon; Catherine E A Heaphy; Violaine Havelange; Muller Fabbri; Stefano Volinia; Twee Tsao; Nicola Zanesi; Steven M Kornblau; Guido Marcucci; George A Calin; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

8.  Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.

Authors:  Hoang V Tran; Arlene S Ash; Joel M Gore; Chad E Darling; Catarina I Kiefe; Robert J Goldberg
Journal:  Am Heart J       Date:  2018-11-01       Impact factor: 4.749

9.  MiR-492 impairs the angiogenic potential of endothelial cells.

Authors:  Francesca Patella; Eleonora Leucci; Monica Evangelista; Brian Parker; Jiayu Wen; Alberto Mercatanti; Milena Rizzo; Elena Chiavacci; Anders H Lund; Giuseppe Rainaldi
Journal:  J Cell Mol Med       Date:  2013-06-26       Impact factor: 5.310

Review 10.  The Role of MicroRNAs in Myocardial Infarction: From Molecular Mechanism to Clinical Application.

Authors:  Teng Sun; Yan-Han Dong; Wei Du; Chun-Ying Shi; Kun Wang; Muhammad-Akram Tariq; Jian-Xun Wang; Pei-Feng Li
Journal:  Int J Mol Sci       Date:  2017-03-31       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.